Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 21;6(2):dlae048.
doi: 10.1093/jacamr/dlae048. eCollection 2024 Apr.

Rates of resistance and heteroresistance to newer β-lactam/β-lactamase inhibitors for carbapenem-resistant Enterobacterales

Christina K Lin  1 , Alex Page  2 , Sarah Lohsen  2 , Ali A Haider  2 , Jesse Waggoner  2 , Gillian Smith  2   3   4 , Ahmed Babiker  2   5 , Jesse T Jacob  2   3 , Jessica Howard-Anderson  2   3 , Sarah W Satola  2   3   5
Affiliations

Rates of resistance and heteroresistance to newer β-lactam/β-lactamase inhibitors for carbapenem-resistant Enterobacterales

Christina K Lin et al. JAC Antimicrob Resist. .

Abstract

Background: Heteroresistance (HR), the presence of antibiotic-resistant subpopulations within a primary isogenic population, may be a potentially overlooked contributor to newer β-lactam/β-lactamase inhibitor (BL/BLI) treatment failure in carbapenem-resistant Enterobacterales (CRE) infections.

Objectives: To determine rates of susceptibility and HR to BL/BLIs ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam in clinical CRE isolates.

Methods: The first CRE isolate per patient per year from two >500 bed academic hospitals from 1 January 2016 to 31 December 2021, were included. Reference broth microdilution (BMD) was used to determine antibiotic susceptibility, and population analysis profiling (PAP) to determine HR. Carbapenemase production (CP) was determined using the Carba NP assay.

Results: Among 327 CRE isolates, 46% were Enterobacter cloacae, 38% Klebsiella pneumoniae and 16% Escherichia coli. By BMD, 87% to 98% of CRE were susceptible to the three antibiotics tested. From 2016 to 2021, there were incremental decreases in the rates of susceptibility to each of the three BL/BLIs. HR was detected in each species-antibiotic combination, with the highest rates of HR (26%) found in K. pneumoniae isolates with imipenem/relebactam. HR or resistance to at least one BL/BLI by PAP was found in 24% of CRE isolates and 65% of these had detectable CP.

Conclusion: Twenty-four percent of CRE isolates tested were either resistant or heteroresistant (HR) to newer BL/BLIs, with an overall decrease of ∼10% susceptibility over 6 years. While newer BL/BLIs remain active against most CRE, these findings support the need for ongoing antibiotic stewardship and a better understanding of the clinical implications of HR in CRE.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percent susceptibility of carbapenem-resistant E. cloacae, E. coli and K. pneumoniae isolates to three novel BL/BLI antibiotics, 2016–21. CZA, ceftazidime/avibactam; IPM/REL, imipenem/relebactam; MEM/VAB, meropenem/vaborbactam.
See this image and copyright information in PMC

References

    1. Martin A, Fahrbach K, Zhao Q et al. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis 2018; 5: ofy150. 10.1093/ofid/ofy150 - DOI - PMC - PubMed
    1. Falagas ME, Tansarli GS, Karageorgopoulos DE et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014; 20: 1170–5. 10.3201/eid2007.121004 - DOI - PMC - PubMed
    1. Kohler PP, Volling C, Green K et al. Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2017; 38: 1319–28. 10.1017/ice.2017.197 - DOI - PubMed
    1. Tamma PD, Bergman Y, Jacobs EB et al. Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates. Infect Control Hosp Epidemiol 2023; 44: 762–7. 10.1017/ice.2022.161 - DOI - PubMed
    1. Dingle TC, Pitout J. The ins and outs of susceptibility testing for new β-lactam/β-lactamase inhibitor combinations for Gram-negative organisms. J Clin Microbiol 2022; 60: e0080721. 10.1128/jcm.00807-21 - DOI - PMC - PubMed

LinkOut - more resources